
    
      The primary objective is to evaluate the change in physical non-sedentary activity as
      measured by the ActiGraph CentrePoint Insight Watch (ActiGraph LLC, Pensacola, Florida) after
      1, 2 and 3 years of treatment with damoctocog alfa pegol.

      Secondary objectives are to determine the

        -  Change in intensity of physical activity,

        -  Association between physical activities and clinical outcomes / patient-reported outcome
           scores/ number of bleeds,

        -  Percentage of patients achieving WHO-recommended levels of activity

        -  Actual wear time.
    
  